

For the attention of:

All participants

28th October 2020

Dear Colleague,

RE: Retention of UKAS Accreditation and new quality development from Diaceutics

The UK Accreditation Service undertook an 'Extension to Scope' assessment to ensure our continued conformity to the ISO 17043 requirements according to their standard procedures following our office relocation on the 12th October. **I am very pleased to report no issues were identified and our accreditation status remains unchanged.**

While writing with this important news I also want to take the opportunity to highlight what I believe may represent a significant advance in the challenge to increase quality in the field of precision medicine that is being launched by Diaceutics today; the Diagnostic Network for Precision Medicine. We at UK NEQAS ICC & ISH have been privileged to have an early insight into this initiative and look forward to seeing it develop and aid the testing community. If you want to find out more follow the link below:

<https://www.diaceutics.com/articles/diaceutics-launches-worlds-first-diagnostic-network-for-precision-medicine-to-solve-global-cancer-testing-issues>

Please do not contact UK NEQAS offices about the DNPM initiative, instead go to Diaceutics directly (<http://www.diaceutics.com/>).

Yours Sincerely



Andrew Dodson
Scheme Director

